News

Safi Biotherapeutics Teams Up with Functional Fluidics for Red Blood Cell Innovation

Safi Biotherapeutics Teams Up with Functional Fluidics for Red Blood Cell Innovation

Safi Biotherapeutics and Functional Fluidics Collaboration

In an exciting development, Safi Biotherapeutics has partnered with Functional Fluidics to enhance the quality and health of manufactured red blood cells (mRBCs). This collaboration focuses on providing crucial support for Safi’s Investigational New Drug (IND) data package. The goal is to use these mRBCs for patients who require chronic transfusions due to sickle cell disease (SCD).

Enhancing Sickle Cell Disease Treatment

This partnership is vital for Safi as they prepare to submit a comprehensive pre-clinical data package to the FDA. Safi Biotherapeutics specializes in creating stem cell-derived, manufactured red blood cell products aimed at improving transfusion practices in both civil and military populations. The involvement of Functional Fluidics, a company known for its expertise in red blood cell health, positions the collaboration for success.

Importance of Collaboration

According to Doug McConnell, CEO and Co-Founder of Safi Biotherapeutics, the validation track record of Functional Fluidics makes them an ideal partner during this critical phase. He emphasized the pressing need for a matched blood supply for patients who undergo regular transfusions, highlighting the importance of their joint efforts in delivering a safe, reliable blood product.

Understanding SCD Challenges

Patients suffering from sickle cell disease often face numerous challenges, particularly concerning alloimmunization risks associated with chronic transfusion therapy. As noted by Patrick Hines, M.D., Ph.D., the CEO of Functional Fluidics, their innovative techniques in producing mRBCs involve targeting specific cell surface antigen profiles. This ensures that patients with SCD receive a safe and dependable blood supply.

Future Directions for mRBCs

While the primary focus remains on addressing chronic transfusions for sickle cell disease, the applications of Safi’s manufactured red blood cells extend to meeting acute transfusion needs in both military and civilian scenarios. Following a successful collaboration with ARMI | BioFabUSA aimed at transitioning mRBCs to current Good Manufacturing Practices (cGMP), Safi is committed to scaling production to a level that meets clinical demands.

About Safi Biotherapeutics

Safi Biotherapeutics is dedicated to advancing the field of red blood cell production. The company was founded with the mission to deliver a characterized cell therapy product that is economically viable for both civilian and military transfusions. With a highly experienced leadership team, including former members from DARPA and Vertex Pharmaceuticals, Safi aims to set new industry standards for RBC manufacturing, addressing urgent needs in chronic and acute transfusion situations.

About Functional Fluidics

Functional Fluidics, established in 2014, is revolutionizing red blood cell health through its precision health technology solutions. The company utilizes advanced healthcare data to expedite the development of innovative therapies, aiding both clinical trials and bridging gaps in patient care. Their global presence across North America and Sub-Saharan Africa strengthens their collaborations with various healthcare entities and pharmaceutical companies.

Frequently Asked Questions

What is the purpose of the Safi and Functional Fluidics collaboration?

The collaboration aims to validate the health and quality of Safi's manufactured red blood cells for use in chronic transfusions, particularly for sickle cell disease.

Who leads Safi Biotherapeutics?

Doug McConnell is the CEO and Co-Founder, leading the company in advancing stem cell-derived RBC products.

What challenges do patients with sickle cell disease face?

Patients face significant challenges such as high risks of alloimmunization, especially when relying on chronic transfusion therapies.

What are manufactured red blood cells (mRBCs)?

Manufactured red blood cells are stem-cell-derived RBCs created to improve transfusion efficacy and safety, addressing both civilian and military needs.

How does Functional Fluidics contribute to this collaboration?

Functional Fluidics offers expertise in red blood cell health and large-scale validation processes, playing a crucial role in supporting Safi's development efforts.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Nonprofit and Partners Gift Homes to Veterans

Updated Category News Views 100

A Heartfelt Gesture on Veterans Day Now this is the kind of story that gets you right in the gut. On November 9, two veterans, who were likely walking into a golf club thinking it was just another evening, were handed the keys to a future they might have only dreamt of: a mortgage-free home. Operation Finally Home, backed by the big names like Lennar and the patriotic...

Continue Reading
Surprising Week on Wall Street: Chips Drive Gains

Updated Category News Views 141

A Wild Week in Wall Street Well, folks, what a week it’s been on Wall Street. The indexes danced the cha-cha, making gains despite closing Friday on a lower note. Despite the retreat, we've got ourselves a week where the major indexes closed higher than the previous Friday. It's not the usual story, but who ever thought stocks played by the rules? The Nasdaq Composite...

Continue Reading
Manhattan Associates Faces Investigation by KSF Law Firm

Updated Category News Views 141

KSF Digs Into Manhattan Associates' Claims In the swirl of the financial world, you rarely see an investigation that doesn’t raise a few eyebrows. This time, it's Manhattan Associates, Inc. (NasdaqGS: MANH) squarely in the crosshairs of Kahn Swick & Foti, LLC (KSF), a pivotal player in securities litigation. You’ve got to wonder what dirt might be uncovered here,...

Continue Reading
Fluence Energy Faces Leadership Departures Amid Legal Woes

Updated Category News Views 83

Fluence Energy's Rocky Road Continues It's chaos once again in the halls of Fluence Energy (NASDAQ:FLNC). The ship seems to drift further from solid ground as their CEO and CFO candidly decided to jump ship, shaking investor confidence even more vigorously. The market's reaction was swift and brutal: a nasty 9% share drop, leaving investors with more than just a headache....

Continue Reading
LA Fitness ELEVATE Opens at RITHM: A New Era Dawns

Updated Category News Views 66

Elevating Fitness at RITHM: A New Era Has Begun RD Management just dropped a new ace in Tampa Bay’s hand—LA Fitness ELEVATE at the RITHM at Uptown. They lit up the scene with this 30,000-square-foot beast of a gym, and I’ll tell you, it’s not your standard run-of-the-mill joint. When you toss twelve-and-a-half million bucks into a pot, you're aiming to lure folks...

Continue Reading
Windward Bio Surges 68% in Nasdaq Debut

Updated Category News Views 134

Windward Bio's Impressive Nasdaq Debut Well, how's that for a debut? Windward Bio, this buzzing clinical-stage biotechnology firm, hit Nasdaq like a storm on November 13, 2026. They priced their IPO at $17.00 per share, but by market close, the stock sat comfortably at $28.50. That's a hearty 68% jump on day one, putting their market value at a sweet $1.69 billion. Behind...

Continue Reading
SmallRig Boosts Art-Driven Innovation in AI Era

Updated Category News Views 99

The Interplay of Art and AI In a world where the lines between man and machine blur faster than ever, creators like SmallRig are boldly asking: what role should authenticity play when AI takes the stage? The Shenzhen International Art Museum and SmallRig stood shoulder to shoulder, tackling this head-scrambling question with a global gathering of art and tech giants. It's...

Continue Reading
WeFetch AI: A New Era in Barcode Precision

Updated Category News Views 155

WeFetch AI: What's in a Name? Forget about GreenCore Solutions Corp. We're talking about WeFetch AI Corp. now. They've just changed their name, fulfilling a bureaucratic tick as of November 13, 2026. But it ain't just a name change; it's a whole new ballgame in AI-driven commerce. AI Shopping Without the Guesswork We've all been there. You think you've ordered that...

Continue Reading
Gemmy's Holiday Lights: Bright Ideas for 2026

Updated Category News Views 149

Deep in the heart of Dallas, Gemmy Industries is out to sprinkle a bit of magic over the holiday season for 2026. This ain't your grandma's string lights we're talkin' about here. We're diving headfirst into a new world of seasonal decor with tech-driven lights that look like they came straight outta a winter wonderland. And hey, if Walmart's set to host this lineup, you...

Continue Reading
Innovent's Seven Drugs Leap onto 2026 Reimbursement Chart

Updated Category News Views 177

A Bold Move in Biopharmaceuticals Innovent Biologics just pulled a rabbit out of their hat. Seven of their cutting-edge meds made it onto China's National Reimbursement Drug List for 2026. This isn't just a spreadsheet entry—it's a lifeline thrown to patients across the oncology, metabolic, and autoimmune landscapes, as well as a financial booster for Innovent (HKEX:...

Continue Reading

Top 5 Most Recently Viewed Articles

NexPoint Capital Launches Tender Offer for Shareholders

Updated Category News Views 217

NexPoint Capital Begins Tender Offer for Its Common Stock NexPoint Capital, Inc. (the "Company"), a publicly registered business development company expertly managed by NexPoint Advisors, L.P., is set to kick off a voluntary tender offer aimed at going after up to 2.5% of its outstanding common shares. This offer is designed to provide shareholders an opportunity to sell...

Continue Reading
Experience the Winter Wheat Wonderland Pop-Up by Maker's Mark

Updated Category News Views 223

Immerse Yourself in Maker's Mark's Winter Wheat Wonderland Get ready to experience something truly unique this holiday season as Maker's Mark unveils its enchanting pop-up event, the Winter Wheat Wonderland. This special event will take the vibrant spirit of Kentucky bourbon to the heart of New York City, creating a magical atmosphere for all attendees. Details of the...

Continue Reading
Innovative Muscle Composition Study Enhances Liver Transplant Care

Updated Category News Views 202

Assessment of Muscle Composition in Liver Transplant Candidates In a groundbreaking study, the utilization of AMRA Profiler 4, an advanced body-composition analysis device, was analyzed for its effectiveness in evaluating muscle composition among liver transplant candidates suffering from end-stage liver disease (ESLD). This study aims to shed light on critical health...

Continue Reading
Hansa Biopharma's Major Milestones Anticipated in 2025

Updated Category News Views 688

Hansa Biopharma's Participation in Healthcare Conferences Hansa Biopharma AB, a pioneering biopharmaceutical company, is set to make a significant presence at the 2025 J.P. Morgan Healthcare Conference. The company is renowned for its innovative approaches in addressing rare immunological disorders and has been actively engaged in developing novel therapies. This...

Continue Reading
AI for Customer Service: The Next Big Market Leap Ahead

Updated Category News Views 137

AI for Customer Service Market Growth Overview The AI for customer service market is on a remarkable trajectory, set to expand significantly over the next few years. Current projections indicate that the market size will grow from USD 12.06 billion in the near term to an impressive USD 47.82 billion by the end of the decade, achieving a compound annual growth rate (CAGR)...

Continue Reading